Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.47 |
| ▸ | CES1 | P23141 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | ITGAL | P20701 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1931608 | 1.00 | CES2 (0.47) | CES2CES1TDP1POLBKDM4E | |
| SCHEMBL15956094 | 0.84 | CES2 (0.49) | CES2CES1POLBKDM4EALDH1A1 | |
| SCHEMBL1012189 | 0.78 | CES2 (0.52) | CES2CES1ALDH1A1RAB9A | |
| SCHEMBL1012187 | 0.78 | CES2 (0.52) | CES2CES1ALDH1A1RAB9A | |
| SCHEMBL14845241 | 0.77 | CES2 (0.50) | CES2CES1RIPK1BCHE | |
| SCHEMBL2998438 | 0.72 | HDAC1 (0.40) | CES2CES1TDP1 | |
| SCHEMBL2998436 | 0.72 | HDAC1 (0.40) | CES2CES1TDP1 | |
| SCHEMBL10442141 | 0.70 | CES2 (0.76) | CES2CES1TDP1RAB9ANPC1 | |
| SCHEMBL15956144 | 0.69 | ALDH1A1 (0.48) | KDM4EALDH1A1RAB9ARIPK1 | |
| SCHEMBL7486005 | 0.68 | STAT3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426598-B2 | N-heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, OPRM1 | CES2 2519/4885CES1 1881/4885TDP1 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.